CN104168903B - 用于治疗由包膜病毒导致的疾病的抑制剂、组合物和疫苗 - Google Patents

用于治疗由包膜病毒导致的疾病的抑制剂、组合物和疫苗 Download PDF

Info

Publication number
CN104168903B
CN104168903B CN201280063973.9A CN201280063973A CN104168903B CN 104168903 B CN104168903 B CN 104168903B CN 201280063973 A CN201280063973 A CN 201280063973A CN 104168903 B CN104168903 B CN 104168903B
Authority
CN
China
Prior art keywords
hiv
virus
cells
antigen
sialoadhesin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280063973.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104168903A (zh
Inventor
努里亚·伊斯基耶多·乌塞罗斯
汉斯-格奥尔格·克罗斯利德
马耶尔·洛里扎泰
哈维尔·马丁内斯·皮卡多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Explore Acquired Immune Deficiency Syndrome (aids) Institute Private Foundation-Deposit Bank
Heidelberg Rupprecht-Ka Ersi University
Institucio Catalana de Recerca i Estudis Avancats ICREA
Original Assignee
Explore Acquired Immune Deficiency Syndrome (aids) Institute Private Foundation-Deposit Bank
Heidelberg Rupprecht-Ka Ersi University
Institucio Catalana de Recerca i Estudis Avancats ICREA
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Explore Acquired Immune Deficiency Syndrome (aids) Institute Private Foundation-Deposit Bank, Heidelberg Rupprecht-Ka Ersi University, Institucio Catalana de Recerca i Estudis Avancats ICREA, Laboratorios del Dr Esteve SA filed Critical Explore Acquired Immune Deficiency Syndrome (aids) Institute Private Foundation-Deposit Bank
Publication of CN104168903A publication Critical patent/CN104168903A/zh
Application granted granted Critical
Publication of CN104168903B publication Critical patent/CN104168903B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201280063973.9A 2011-12-22 2012-12-17 用于治疗由包膜病毒导致的疾病的抑制剂、组合物和疫苗 Expired - Fee Related CN104168903B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579242P 2011-12-22 2011-12-22
EP11382392.6 2011-12-22
US61/579,242 2011-12-22
EP11382392.6A EP2606897A1 (en) 2011-12-22 2011-12-22 Methods and compositions for the treatment of diseases caused by enveloped viruses
PCT/EP2012/075831 WO2013092509A1 (en) 2011-12-22 2012-12-17 Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses

Publications (2)

Publication Number Publication Date
CN104168903A CN104168903A (zh) 2014-11-26
CN104168903B true CN104168903B (zh) 2017-05-31

Family

ID=45445920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280063973.9A Expired - Fee Related CN104168903B (zh) 2011-12-22 2012-12-17 用于治疗由包膜病毒导致的疾病的抑制剂、组合物和疫苗

Country Status (14)

Country Link
US (1) US9789130B2 (enExample)
EP (2) EP2606897A1 (enExample)
JP (1) JP6143781B2 (enExample)
KR (1) KR20140130664A (enExample)
CN (1) CN104168903B (enExample)
AU (1) AU2012357968B2 (enExample)
BR (1) BR112014015112A8 (enExample)
CA (1) CA2858499A1 (enExample)
HK (1) HK1202820A1 (enExample)
IL (1) IL233207A0 (enExample)
MX (1) MX2014007605A (enExample)
RU (1) RU2014130022A (enExample)
WO (1) WO2013092509A1 (enExample)
ZA (1) ZA201403861B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11249081B2 (en) 2016-08-31 2022-02-15 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004695B2 (en) 2014-04-16 2018-06-26 Trustees Of Boston University GM3 functionalized nanoparticles
CN104587491A (zh) * 2014-12-30 2015-05-06 天津大学 SAMHD1-pLNCX2制备抗肿瘤药物的用途
AU2017261840A1 (en) * 2016-05-06 2018-11-22 WRS Nutraceuticals Pty Ltd Agent delivery system
CN108165559B (zh) * 2017-11-29 2021-06-18 昆明理工大学 一种c2h2型转录因子基因及其应用
KR20230099676A (ko) * 2021-12-27 2023-07-04 주식회사 진켐 시알릴락토스를 이용한 혈뇌장벽 투과용 약물 전달체
US20250302865A1 (en) * 2022-03-16 2025-10-02 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
KR20240102304A (ko) * 2022-12-26 2024-07-03 주식회사 진켐 신규한 젬시타빈 결합체 및 이의 용도
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3888975A (en) 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (enExample) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NL7807532A (nl) 1978-07-13 1980-01-15 Akzo Nv Metaal-immunotest.
FR2433949A1 (fr) 1978-08-25 1980-03-21 Commissariat Energie Atomique Substrat hydrophobe apte a liberer une substance chimique
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4360013A (en) 1980-04-21 1982-11-23 Minnesota Mining And Manufacturing Company Polymeric acid contraceptive devices
IT1131833B (it) 1980-06-20 1986-06-25 Crinos Industria Farmaco Eccipienti per sostanze spermicide
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4368186A (en) 1981-05-07 1983-01-11 Syntex (U.S.A.) Inc. Methods and compositions for intravaginal contraception
US4415585A (en) 1982-03-11 1983-11-15 University Of Illinois Foundation Contraceptive method
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5248700A (en) 1982-05-14 1993-09-28 Akzo Nv Active agent containing solid structures for prolonged release of active agents
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4499154A (en) 1982-09-03 1985-02-12 Howard L. Podell Dipped rubber article
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
DE4015543A1 (de) 1990-05-15 1991-11-21 Bayer Ag Spermicides beschichtungsmittel
DE69119312T2 (de) 1990-07-18 1997-01-16 Abbott Lab Analyt-Austauschreagenz zur Verwendung in spezifischen Bindungstests, -vorrichtungen und -sätzen
US5143731A (en) 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
FR2666587B1 (fr) 1990-09-10 1993-06-25 Dow Corning Sa Compositions de lubrifiant et leur utilisation.
GB9021061D0 (en) 1990-09-27 1990-11-07 Unilever Plc Encapsulating method and products containing encapsulated material
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
IL105503A (en) 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5759781A (en) 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5876935A (en) 1997-01-08 1999-03-02 Dade Behring Inc. Luminescent specific binding assay
SE9700383D0 (sv) 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
CA2340118C (en) 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
EP1168924A4 (en) 1999-03-31 2002-09-04 Univ Pittsburgh DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
US20030092091A1 (en) * 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
MXPA03005373A (es) 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
JP5231231B2 (ja) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
JP5641598B2 (ja) * 2009-09-29 2014-12-17 雪印メグミルク株式会社 シアリルラクトース素材の分離方法
JP5788653B2 (ja) * 2010-09-10 2015-10-07 靖人 江原 糖鎖修飾ヌクレオチド及びその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11249081B2 (en) 2016-08-31 2022-02-15 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof

Also Published As

Publication number Publication date
AU2012357968B2 (en) 2017-10-05
MX2014007605A (es) 2015-07-06
US20140370052A1 (en) 2014-12-18
RU2014130022A (ru) 2016-02-10
CA2858499A1 (en) 2013-06-27
EP2606897A1 (en) 2013-06-26
US9789130B2 (en) 2017-10-17
EP2793904A1 (en) 2014-10-29
IL233207A0 (en) 2014-07-31
JP6143781B2 (ja) 2017-06-07
JP2015500854A (ja) 2015-01-08
HK1202820A1 (en) 2015-10-09
CN104168903A (zh) 2014-11-26
BR112014015112A2 (pt) 2017-06-13
WO2013092509A1 (en) 2013-06-27
NZ627650A (en) 2016-01-29
KR20140130664A (ko) 2014-11-11
BR112014015112A8 (pt) 2017-06-13
AU2012357968A1 (en) 2014-08-14
ZA201403861B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
CN104168903B (zh) 用于治疗由包膜病毒导致的疾病的抑制剂、组合物和疫苗
Meås et al. Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
ES2397355T5 (es) Métodos y composiciones para el tratamiento de infecciones persistentes y cáncer por inhibición de la vía de muerte celular programada (PD-1)
Klatt Pathology of AIDS
Gummuluru et al. CD169-dependent cell-associated HIV-1 transmission: a driver of virus dissemination
Guardo et al. Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)
CN101557823A (zh) 人内源性逆转录病毒多肽组合物和其使用方法
Verma et al. Impact of Th1 CD4 follicular helper T cell skewing on antibody responses to an HIV-1 vaccine in rhesus macaques
KR101651304B1 (ko) Ｈｍｇｂ1 의존적인 ｈｉｖ-1 복제 및 지속감염 촉발의 조절에 의한 인간 면역결핍 바이러스 감염의 모니터링 및 억제
Kijewski et al. Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated
CN113866416B (zh) 可溶形式Tim3在免疫检查点阻断治疗抵抗的应用
NZ627650B2 (en) Inhibitors of sialoadhesin for the treatment of diseases caused by enveloped viruses
Zhou et al. Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy
Valencia Hernandez Inducing immunity to liver stage malaria through endogenous tissue resident memory cells
Benet Impact of a SIGLEC1 null variant on the pathogenesis of HIV-1 and Mtb infection
Karaji Characterisation of an “eat-me” signal on dying and HIV-1-infected T cells
Kang et al. HIV Virion Capturing Liposomes for Therapeutic Vaccination
Hertoghs et al. Mucosal dendritic cells in HIV-1 susceptibility: a critical role for C-type lectin receptors
Yoshizawa et al. Studies on the generation and maintenance of mucosal cytotoxic T lymphocytes against human immunodeficiency virus type 1 Gag in mice
Berzi et al. EVALUATION OF ANTI-INFECTIVE ACTIVITY OF GLYCOMIMETIC DC-SIGN LIGANDS
Arunachalam et al. Toll-like receptor 9 activation rescues impaired antibody response in needle-free intradermal DNA vaccination
Inizan Human Immunodeficiency Virus Type I subverts T cell extracellular matrix to shelter cell-associated infectivity in a viral biofilm
Nowroozalizadeh Activation and dysregulation of innate immunity in HIV-1 and HIV-2 infections
Hebbandi Nanjundappa HIV-1 Glycoprotein 120-Specific Exosome-Targeted CD8+ T Cell Vaccine
Benet Garrabé Impact of a SIGLEC1 null variant on the pathogenesis of HIV-1 and Mtb infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190201

Address after: Badalona, Spain

Co-patentee after: Catalan the first Advanced Study Institutes

Patentee after: Explore acquired immune deficiency syndrome (AIDS) institute private foundation-deposit bank

Co-patentee after: Heidelberg Rupprecht-Ka Ersi university

Address before: Spain Barcelona

Co-patentee before: Explore acquired immune deficiency syndrome (AIDS) institute private foundation-deposit bank

Patentee before: Esteve Labor Dr.

Co-patentee before: Catalan the first Advanced Study Institutes

Co-patentee before: Heidelberg Rupprecht-Ka Ersi university

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170531

Termination date: 20191217